- Home
- HROW vs ANIP Comparison
HROW vs ANIP Comparison
Compare HROW & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- ANIP
- Stock Information
- Founded
- HROW 1998
- ANIP 2001
- Country
- HROW United States
- ANIP United States
- Employees
- HROW N/A
- ANIP N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- HROW Health Care
- ANIP Health Care
- Exchange
- HROW Nasdaq
- ANIP Nasdaq
- Market Cap
- HROW 1.3B
- ANIP 1.2B
- IPO Year
- HROW N/A
- ANIP N/A
- Fundamental
- Price
- HROW $33.85
- ANIP $58.46
- Analyst Decision
- HROW Strong Buy
- ANIP Buy
- Analyst Count
- HROW 4
- ANIP 7
- Target Price
- HROW $55.00
- ANIP $77.33
- AVG Volume (30 Days)
- HROW 328.0K
- ANIP 257.7K
- Earning Date
- HROW 11-13-2024
- ANIP 02-27-2025
- Dividend Yield
- HROW N/A
- ANIP N/A
- EPS Growth
- HROW N/A
- ANIP N/A
- EPS
- HROW N/A
- ANIP N/A
- Revenue
- HROW $169,138,000.00
- ANIP $555,456,000.00
- Revenue This Year
- HROW $50.31
- ANIP $25.48
- Revenue Next Year
- HROW $47.75
- ANIP $20.24
- P/E Ratio
- HROW N/A
- ANIP N/A
- Revenue Growth
- HROW 48.15
- ANIP 23.60
- 52 Week Low
- HROW $9.13
- ANIP $52.50
- 52 Week High
- HROW $59.23
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- HROW 41.48
- ANIP 62.05
- Support Level
- HROW $32.93
- ANIP $52.74
- Resistance Level
- HROW $36.13
- ANIP $55.21
- Average True Range (ATR)
- HROW 1.88
- ANIP 1.54
- MACD
- HROW 0.18
- ANIP 0.48
- Stochastic Oscillator
- HROW 28.60
- ANIP 98.11
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.